Please note – you will leave a website owned by MacroGenics, Inc.
MacroGenics is not responsible for any content on the third party website.
Background
MGD019 is an investigational, bispecific DART® molecule that was designed to enhance CTLA-4 blockade on dual-expressing, tumor-infiltrating lymphocytes compared to a PD-1/CTLA-4 monoclonal antibody (mAb) combination therapy, while maintaining maximal PD-1 blockade on all PD-1-expressing cells.
Clinical Development
Based upon the establishment of a recommended Phase 2 dose from a dose escalation study, MGD019 is initially being evaluated in a dose expansion study in microsatellite-stable colorectal cancer and non-small cell lung cancer.
Our Rights
MacroGenics retains global rights to MGD019.
Clinical Trials
Presentations & Publications
Relevant Publications and Presentations can be found at https://www.macrogenics.com/publications/.
The safety and efficacy of investigational agents and/or investigational uses of approved products have not been established.